Patients & caregivers
If you are living with Alzheimer’s disease, read this first.
We cannot provide hydralazine for Alzheimer’s disease. NeuroNova is not currently enrolling patients in any clinical trial. Please do not stop, start, or change any medication based on information on this site. Speak with your physician. For information about Alzheimer’s disease and support services, contact the Alzheimer’s Association at 800-272-3900 or alz.org. For clinical trials currently enrolling, see clinicaltrials.gov.
Hydralazine is approved in the United States for high blood pressure. It is not approved for Alzheimer’s disease, and NeuroNova cannot provide it for that use. Whether hydralazine has any benefit in Alzheimer’s disease has not been established.
If a future clinical trial in the United States begins enrolling, information will be available through clinicaltrials.gov.
Reporting an adverse event
Suspected adverse events involving marketed hydralazine products can be reported to FDA MedWatch at 1-800-FDA-1088. You may also notify us at harrison.mirzaei@neuronovatherapeutics.com.
Hydralazine is an investigational treatment for Alzheimer’s disease. It has not been approved by the U.S. Food and Drug Administration or any other regulatory authority for this use. Its safety and effectiveness for Alzheimer’s disease have not been established.